{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:02:23Z","timestamp":1766023343664,"version":"3.48.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Exp Urol"],"DOI":"10.62347\/tmqg2381","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T02:49:57Z","timestamp":1751338197000},"page":"215-224","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in men with benign prostatic hyperplasia and overactive bladder in a prospective randomized controlled trial"],"prefix":"10.62347","volume":"13","author":[{"given":"Yu-Rui","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","article-title":"Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial","volume":"212","author":"Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K and Mujais S. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol 2024; 212: 256-266.","journal-title":"J Urol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/nau.25399","article-title":"Safety and efficacy of an α1-blocker plus mirabegron compared with an α1-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis","volume":"43","author":"Herschorn","year":"2024","unstructured":"Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A and Sumarsono B. Safety and efficacy of an α1-blocker plus mirabegron compared with an α1-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis. Neurourol Urodyn 2024; 43: 604-619.","journal-title":"Neurourol Urodyn"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11934-017-0649-z","article-title":"Treatment of concomitant OAB and BPH","volume":"18","author":"Moss","year":"2017","unstructured":"Moss MC, Rezan T, Karaman UR and Gomelsky A. Treatment of concomitant OAB and BPH. Curr Urol Rep 2017; 18: 1.","journal-title":"Curr Urol Rep"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Shapiro KK and Brucker BM. Treatment of overactive bladder in men: is it really different? Neurourol Urodyn 2022; 41: 1975-1982.","DOI":"10.1002\/nau.25000"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s41999-023-00798-7","article-title":"Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review","volume":"14","author":"&#x130","year":"2023","unstructured":"İlhan B, Erdoğan T, Topinková E and Bahat G; EuGMS Task and Finish Group on FRIDs. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. Eur Geriatr Med 2023; 14: 733-746.","journal-title":"Eur Geriatr Med"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Su S, Lin J, Liang L, Liu L, Chen Z and Gao Y. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e18802.","DOI":"10.1097\/MD.0000000000018802"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/luts.12197","article-title":"Effects of magnetic stimulation on urodynamic stress incontinence refractory to pelvic floor muscle training in a randomized sham-controlled study","volume":"11","author":"Yamanishi","year":"2019","unstructured":"Yamanishi T, Suzuki T, Sato R, Kaga K, Kaga M and Fuse M. Effects of magnetic stimulation on urodynamic stress incontinence refractory to pelvic floor muscle training in a randomized sham-controlled study. Low Urin Tract Symptoms 2019; 11: 61-65.","journal-title":"Low Urin Tract Symptoms"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"18404","DOI":"10.1038\/s41598-024-69345-z","article-title":"A randomized controlled trial of low-frequency repeated transcranial magnetic stimulation in patients with poststroke neurogenic bladder","volume":"14","author":"Chen","year":"2024","unstructured":"Chen J, Tan B, Chen Y, Song Y, Li L, Yu L, Feng Y, Zhou Y and Jiang W. A randomized controlled trial of low-frequency repeated transcranial magnetic stimulation in patients with poststroke neurogenic bladder. Sci Rep 2024; 14: 18404.","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3390\/jcm12093157","article-title":"Pelvic floor muscle training versus functional magnetic stimulation for stress urinary incontinence in women: a randomized controlled trial","volume":"12","author":"Dudonien&#x117","year":"2023","unstructured":"Dudonienė V, Kirklytė I, Žlibinaitė L, Jerez-Roig J and Rutkauskaitė R. Pelvic floor muscle training versus functional magnetic stimulation for stress urinary incontinence in women: a randomized controlled trial. J Clin Med 2023; 12: 3157.","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10072-024-07788-y","article-title":"Comparative study on the impact of transcranial magnetic stimulation and Bio-feedback on overactive bladder in multiple sclerosis patients: a randomized clinical trial","volume":"46","author":"Raheem","year":"2025","unstructured":"Raheem OMA and Abdel-Hady DA. Comparative study on the impact of transcranial magnetic stimulation and Bio-feedback on overactive bladder in multiple sclerosis patients: a randomized clinical trial. Neurol Sci 2025; 46: 1291-1299.","journal-title":"Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2147\/IJWH.S372597","article-title":"Mirabegron in the management of overactive bladder syndrome","volume":"14","author":"O&#x2019","year":"2022","unstructured":"O’Kane M, Robinson D, Cardozo L, Wagg A and Abrams P. Mirabegron in the management of overactive bladder syndrome. Int J Womens Health 2022; 14: 1337-1350.","journal-title":"Int J Womens Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/luts.12415","article-title":"How international is the international prostate symptom score? A literature review of validated translations of the IPSS, the most widely used self-administered patient questionnaire for male lower urinary tract symptoms","volume":"14","author":"Yao","year":"2022","unstructured":"Yao MW and Green JSA. How international is the international prostate symptom score? A literature review of validated translations of the IPSS, the most widely used self-administered patient questionnaire for male lower urinary tract symptoms. Low Urin Tract Symptoms 2022; 14: 92-101.","journal-title":"Low Urin Tract Symptoms"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12325-019-0880-8","article-title":"Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review","volume":"36","author":"KM","year":"2019","unstructured":"Johnston KM, Walker DR and Lakzadeh P. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Adv Ther 2019; 36: 548-562.","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41598-020-79974-9","article-title":"Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version","volume":"11","author":"Sawaqed","year":"2021","unstructured":"Sawaqed F and Suoub M. Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version. Sci Rep 2021; 11: 661.","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1373375","DOI":"10.3389\/fnins.2024.1373375","article-title":"Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study","volume":"18","author":"Liang","year":"2024","unstructured":"Liang P, Tang QL, Lin T, Tang ZK, Liu FD, Zhou XZ and Tao RZ. Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study. Front Neurosci 2024; 18: 1373375.","journal-title":"Front Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"554078","DOI":"10.3389\/fendo.2021.554078","article-title":"Endocrinology of the aging prostate: current concepts","volume":"12","author":"Cannarella","year":"2021","unstructured":"Cannarella R, Condorelli RA, Barbagallo F, La Vignera S and Calogero AE. Endocrinology of the aging prostate: current concepts. Front Endocrinol (Lausanne) 2021; 12: 554078.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11255-018-02071-4","article-title":"Predictors for immediate recovery of continence following Retzius-sparing robot-assisted radical prostatectomy: a case-control study","volume":"51","author":"Qin","year":"2019","unstructured":"Qin H, Qiu X, Ma H, Xu L, Xu L, Li X and Guo H. Predictors for immediate recovery of continence following Retzius-sparing robot-assisted radical prostatectomy: a case-control study. Int Urol Nephrol 2019; 51: 825-830.","journal-title":"Int Urol Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1464-410X.2005.05686.x","article-title":"Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies","volume":"96","author":"Roehrborn","year":"2005","unstructured":"Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J and Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96: 572-7.","journal-title":"BJU Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/01913123.2018.1462874","article-title":"Pathophysiological effect of bladder outlet obstruction on the urothelium","volume":"42","author":"Niemczyk","year":"2018","unstructured":"Niemczyk G, Czarzasta K, Radziszewski P, Włodarski P and Cudnoch-Jędrzejewska A. Pathophysiological effect of bladder outlet obstruction on the urothelium. Ultrastruct Pathol 2018; 42: 317-322.","journal-title":"Ultrastruct Pathol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.acuro.2024.04.004","article-title":"Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity","volume":"48","author":"Borau","year":"2024","unstructured":"Borau A, Salinas J, Allué M, Castro-Diaz D, Esteban M, Arlandis S, Virseda M and Adot JM. Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity. Actas Urol Esp (Engl Ed) 2024; 48: 674-682.","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajur.2017.06.003","article-title":"Pathophysiology of clinical benign prostatic hyperplasia","volume":"4","author":"Foo","year":"2017","unstructured":"Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4: 152-157.","journal-title":"Asian J Urol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11934-012-0281-x","article-title":"LUTS and sleep disorders: emerging risk factor","volume":"13","author":"Cakir","year":"2012","unstructured":"Cakir OO and McVary KT. LUTS and sleep disorders: emerging risk factor. Curr Urol Rep 2012; 13: 407-12.","journal-title":"Curr Urol Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ucl.2021.12.003","article-title":"Medical treatment of benign prostatic hyperplasia","volume":"49","author":"Plochocki","year":"2022","unstructured":"Plochocki A and King B. Medical treatment of benign prostatic hyperplasia. Urol Clin North Am 2022; 49: 231-238.","journal-title":"Urol Clin North Am"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","unstructured":"Deeks ED. Mirabegron: a review in overactive bladder syndrome. Drugs 2018; 78: 833-844.","journal-title":"Drugs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E and Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014; 33: 17-30.","journal-title":"Neurourol Urodyn"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/luts.12087","article-title":"Neuromodulation for the treatment of lower urinary tract symptoms","volume":"7","author":"Yamanishi","year":"2015","unstructured":"Yamanishi T, Kaga K, Fuse M, Shibata C and Uchiyama T. Neuromodulation for the treatment of lower urinary tract symptoms. Low Urin Tract Symptoms 2015; 7: 121-32.","journal-title":"Low Urin Tract Symptoms"},{"key":"ref26","unstructured":"Zhou D, Wang JW, Wang SJ, Shi CL, Shi GW, Wang YY and Xu K. Magnetic stimulation combined with moxibustion improves mild to moderate overactive bladder and sexual function in women. Zhonghua Nan Ke Xue 2024; 30: 249-253."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.clinph.2019.08.020","article-title":"Transcranial magnetic stimulation and bladder function: a systematic review","volume":"130","author":"Nardone","year":"2019","unstructured":"Nardone R, Versace V, Sebastianelli L, Brigo F, Golaszewski S, Christova M, Saltuari L and Trinka E. Transcranial magnetic stimulation and bladder function: a systematic review. Clin Neurophysiol 2019; 130: 2032-2037.","journal-title":"Clin Neurophysiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/iju.12289","article-title":"Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence","volume":"21","author":"Yamanishi","year":"2014","unstructured":"Yamanishi T, Homma Y, Nishizawa O, Yasuda K and Yokoyama O; SMN-X Study Group. Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. Int J Urol 2014; 21: 395-400.","journal-title":"Int J Urol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3390\/jcm12175455","article-title":"The effects of extracorporeal magnetic innervation in the treatment of women with urinary incontinence: a systematic review","volume":"12","author":"Strojek","year":"2023","unstructured":"Strojek K, Strączyńska A, Radzimińska A and Weber-Rajek M. The effects of extracorporeal magnetic innervation in the treatment of women with urinary incontinence: a systematic review. J Clin Med 2023; 12: 5455.","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00345-024-04974-7","article-title":"The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder","volume":"42","author":"Hagovska","year":"2024","unstructured":"Hagovska M, Svihra J Sr, Macko L, Breza J Jr, Svihra J Jr, Luptak J and Lachvac L. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World J Urol 2024; 42: 287.","journal-title":"World J Urol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.neurom.2022.04.034","article-title":"Transcutaneous Tibial nerve stimulation in the management of overactive bladder: a scoping review","volume":"25","author":"Sayner","year":"2022","unstructured":"Sayner AM, Rogers F, Tran J, Jovanovic E, Henningham L and Nahon I. Transcutaneous Tibial nerve stimulation in the management of overactive bladder: a scoping review. Neuromodulation 2022; 25: 1086-1096.","journal-title":"Neuromodulation"}],"container-title":["American Journal of Clinical and Experimental Urology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajceu\/13\/3\/ajceu0165294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:30Z","timestamp":1766023050000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajceu\/13\/3\/ajceu0165294.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/tmqg2381","relation":{},"ISSN":["2330-1910"],"issn-type":[{"type":"electronic","value":"2330-1910"}],"subject":[],"published":{"date-parts":[[2025]]}}}